search
Back to results

Oral Nifedipine Versus Oral Labetalol

Primary Purpose

Severe Postpartum Hypertension

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Labetalol
Nifedipine
Sponsored by
Cedars-Sinai Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Severe Postpartum Hypertension

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years with the abililty to give informed consent
  • Intrauterine pregnancy ≥ 32 weeks
  • Postpartum
  • Persistent postpartum blood pressures ≥ 160/105 on two or more occasions
  • Primary obstetrician amenable to starting either study medication in the postpartum period

Exclusion Criteria:

  • Use of other oral antihypertensives concomitantly
  • Known AV heart block
  • HR <60 or >120
  • Absolute contraindication to nifedipine or labetolol such as allergy
  • Significant renal disease (Cr >1.5 mg/dL)
  • Heart failure
  • Moderate persistent or severe asthma
  • Preexisting diagnosis of chronic hypertension with medical treatment before delivery
  • Chronic hypertension

Sites / Locations

  • Cedars Sinai Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Labetalol

Nifedipine

Arm Description

Labetalol 200mg PO BID starting dose

Nifedpine XL starting at dose 30mg PO daily

Outcomes

Primary Outcome Measures

Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication
Primary outcome

Secondary Outcome Measures

Total Length of Hospital Stay in Days
Secondary outcome

Full Information

First Posted
June 17, 2014
Last Updated
November 15, 2017
Sponsor
Cedars-Sinai Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02168309
Brief Title
Oral Nifedipine Versus Oral Labetalol
Official Title
Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cedars-Sinai Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study's aim is to determine whether oral extended release nifedipine is superior to oral labetolol for the management of postpartum severe hypertension, specifically time to achieve goal blood pressure, and shortening hospital stay. Our hypothesis is that oral extended release nifedipine is superior to oral labetolol for achieving goal blood pressure in the postpartum period.
Detailed Description
Hypertension complicating pregnancy is common and, when uncontrolled, can have devastating consequences. While the true incidence of postpartum hypertension is unknown, blood pressure (BP) is known to initially decrease 48 hours following delivery then peak on postpartum days 3-6, likely 45 from the mobilization of interstitial fluids following parturition. The American College of Obstetricians and Gynecologists (ACOG) recommends medical treatment of persistent postpartum hypertension, defined as systolic BP (SBP) ≥150 mmHg or diastolic BP (DBP) ≥100 mmHg, on two or more occasions 4-6 hours apart. Prior studies compared intravenous medications to intramuscular and immediate-release oral 50 medications in the treatment of postpartum hypertension. However, oral labetalol and oral extended release nifedipine are the most commonly used medications for post- partum hypertension, and their efficacy has not been directly compared. Our aim was to determine whether oral labetalol is associated with a shorter time to BP control compared to oral extended release nifedipine for management of persistent 55 postpartum hypertension. Our primary outcome was time to sustained BP control defined as the absence of severe hypertension (SBP ≥160 mmHg or DBP ≥105 mmHg) for at least 12 hours. Secondary outcomes included postpartum length of stay, need for increased dosing, need for additional oral antihypertensive agents, and patient-reported side effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Postpartum Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Labetalol
Arm Type
Other
Arm Description
Labetalol 200mg PO BID starting dose
Arm Title
Nifedipine
Arm Type
Other
Arm Description
Nifedpine XL starting at dose 30mg PO daily
Intervention Type
Drug
Intervention Name(s)
Labetalol
Other Intervention Name(s)
Oral labetalol starting at dose 200mg PO BID
Intervention Description
Titrate up for blood pressure control
Intervention Type
Drug
Intervention Name(s)
Nifedipine
Other Intervention Name(s)
Oral nifedipine 30mg XL PO starting
Intervention Description
Titrate up to achieve blood pressure control
Primary Outcome Measure Information:
Title
Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication
Description
Primary outcome
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Total Length of Hospital Stay in Days
Description
Secondary outcome
Time Frame
0-10 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years with the abililty to give informed consent Intrauterine pregnancy ≥ 32 weeks Postpartum Persistent postpartum blood pressures ≥ 160/105 on two or more occasions Primary obstetrician amenable to starting either study medication in the postpartum period Exclusion Criteria: Use of other oral antihypertensives concomitantly Known AV heart block HR <60 or >120 Absolute contraindication to nifedipine or labetolol such as allergy Significant renal disease (Cr >1.5 mg/dL) Heart failure Moderate persistent or severe asthma Preexisting diagnosis of chronic hypertension with medical treatment before delivery Chronic hypertension
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah Kilpatrick
Organizational Affiliation
Cedars-Sinai Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cedars Sinai Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27786578
Citation
Sharma KJ, Greene N, Kilpatrick SJ. Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial. Hypertens Pregnancy. 2017 Feb;36(1):44-47. doi: 10.1080/10641955.2016.1231317. Epub 2016 Oct 27.
Results Reference
derived

Learn more about this trial

Oral Nifedipine Versus Oral Labetalol

We'll reach out to this number within 24 hrs